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Abstract 
Problem: Perinatal mood disorders, including depression, affects one in five pregnant or 
postpartum females. The American College of Obstetricians and Gynecologists (ACOG) 
and the US Preventative Task Force (USPTF) recommended screening for depression at 
least once during the antepartum and postpartum periods.  The purpose of this quality 
improvement initiative was to introduce depression screening using the patient health 
questionnaire (PHQ) in antepartum women in a Midwestern private OB-GYN practice. 
Methods:  An observational, descriptive, cohort design utilizing a retrospective record 
review was used to evaluate for PHQ depression screening. A convenience sample of 
antepartum patients at/or around 36-weeks gestation was studied.  A Plan-do-study-act 
(PDSA) cycle was utilized. 
Results: There were 66 prenatal visits from January 2nd through March 20th, 2019.  Of 
those, 54 patients (N=54) were screened with the PHQ-2 and four were screened further 
with the PHQ-9 (n=4).  Most women screened negative for antepartum depression at 36-
weeks gestation (n=50), but the PHQ-2 identified four at risk and in need of further 
evaluation with the PHQ-9 (χ2=39.19, df = 1,  p<0.001); hence, approximately one in 
twenty patients screened positive for depression at/or around 36-weeks gestation.  All 
patients who screened positive on the PHQ-9 were treated with medication and referred for 
counseling services.  
Implications for Practice: Early identification of depression in pregnant females allowed 
for early medication management and counseling services.  Further study is needed to 
determine if depression treatment during the antepartum period impacts the postpartum 
period.   
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Depression Screening in Antepartum Females 
Currently in the United States, perinatal mood disorders affect approximately 15 
to 21% of antepartum and postpartum females (Byrnes, 2018).  There is a significant 
difference between “baby blues” (a less severe form of postpartum depression), clinical 
postpartum depression and psychosis.  Baby blues immediately postpartum comprises 40-
80% of depressive symptoms (Byrnes, 2018).  Screening for more severe depression in 
obstetrics and gynecology practices (OBGYN) is recommended and may assist providers 
in accurately diagnosing mental health changes during the perinatal period.  The 
American College of Obstetricians and Gynecologists (ACOG) has advocated for patients 
to be screened with a validated depression screening tool at least once during the 
perinatal period (Avalos, Raine-Bennett, Chen, Adams & Flanagan, 2016).  However, the 
US Preventative Task Force (USPTF) recommended females to be screened for 
depression at least once during the antepartum period and once during the postpartum 
period (Brown, 2018).   
In general, depression can affect females more than males.  Depression in females 
can cause significant life-long disabilities (Fairbrother, Young, Janssen, Antony & 
Tucker, 2015).  Fairbrother et al., (2015) reported depression may be a leading cause of 
disability related to the disorder.  Females are also 1.6 to 1.7 times more likely than men 
to experience depressive symptoms overall (Fairbrother et al., 2015).  Perinatal 
depression includes depressive episodes occurring during pregnancy and in the 
postpartum period.  The postpartum period is defined as the first twelve months after 
delivery (Fairbrother et al., 2015).   Hence, one in seven females may experience 
perinatal and postpartum depression (Silverman et al., 2017).   
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The Patient Health Questionnaire (PHQ) is the most widely used depression 
screening tool in primary care and OB-GYN practices (Kroenke, Spitzer, & Williams, 
2003).  The PHQ-2 includes two questions, and if positive, a PHQ-9 containing nine 
questions, may provide more information.  The PHQ-2 and PHQ-9 have a high sensitivity 
and specificity for identifying depression risk (Sit & Wisner, 2009).  With any positive 
screen, the recommendation is to have the patient further evaluated for moderate to 
severe depression and to consider treatment options.   
The purpose of this quality improvement initiative was to introduce depression 
screening using the PHQ-2 and/or PHQ-9 in antepartum women in a Midwestern private 
OB-GYN practice.  Currently, there is not a standardized depression screening tool used 
during the antepartum and postpartum periods within the practice.  Often the provider 
determined if the patient was at risk for depression by asking non-standardized questions.  
Implementation of the PHQ-2 and PHQ-9 may provide a standardized, validated 
screening process during the perinatal period for the practice.  In addition, early 
identification of depression in antepartum females may facilitate early treatment (if 
needed) and decrease the risk of a more severe postpartum depression from occurring.  
The questions for study included:  
In pregnant women aged 18-45 years at/or around 36-weeks gestation,  
1. what was the rate of PHQ-2 screening? 
2. when the PHQ-2 indicated increased depression risk, what was the rate of PHQ-9 
screening? 
3. of those identified as increased risk for depression, what was the rate of those who 
received treatment (medication) or referral to a mental health provider?   
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Review of the Literature 
 The search engines used were Cochrane Library, CINAHL, and PUBMED.  The 
search included the terms: depression screening tools, pregnant females, antepartum 
AND postpartum females, PHQ-2 AND PHQ-9.  The search included literature from the 
years 2008-2018.  Most of the literature reviewed was from 2013-2018.  There was a 
more advanced search that identified depression screening from 2003-2018.  The 
inclusion criteria included only adult females equal to or above age 18-years and PHQ 
depression screening.  The exclusion criteria were females below age 18-years and other 
screening tools for depression.  There were 20 publications selected for this literature 
review.   
The prevalence of postpartum depression is approximately 10% in the obstetrical 
patient (Viguera, Tondo, Koukopoulos, Reginaldi, Lepri & Baldessarini, 2011).  In a 
retrospective study, Viguera et al., (2011) evaluated the prevalence of antepartum and 
postpartum depression.  Clinical datasets of greater than 200,000 antepartum women and 
greater than 4,000 postpartum women were reviewed (Viguera et al., 2011).  They found 
in at least 1,000 pregnant women with depression, the risk of perinatal depression was 
more than double with a prior history of depression (Viguera et al., 2011).  Viguera et al. 
(2011) also found screening all postpartum women for depression was important in 
identifying those who might chronically suffer from the disorder.  
There are several factors affecting perinatal depression.  One reason for the higher 
incidence of depression during pregnancy might be a rapid fluctuation of hormones 
during pregnancy.  With pregnancy, the estrogen and progesterone levels are significantly 
elevated.  Schiller, Melzer-Brody and Rubinow (2014) reported the fluctuations in 
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hormones during pregnancy may lead to depressive symptoms during pregnancy and 
postpartum in susceptible women.  They emphasized every reproductive hormone can 
influence virtually every biological state (Schiller et al., 2014).  Likewise, Viguera et al., 
(2011) found supporting evidence of endocrine factors being involved in the pathogenesis 
of depression during pregnancy.  Elevated levels of corticotropin-releasing hormones at 
25-weeks gestation was identified as a strong predictor of postpartum depression 
(Viguera et al., 2011).   
The PHQ-2 and PHQ-9 are validated depression screening tools and are the most 
commonly used instruments for adults.  Maurer (2012) reported the PHQ-2 contains two 
questions with a 97% sensitivity and 67% specificity for detecting depression.  The PHQ-
9 has nine questions with a 61% sensitivity and 94% specificity in the adult population 
(Maurer, 2012).  When a PHQ-2 is found to be positive for depression, further screening 
is recommended using the PHQ-9 (Mauer, 2012).  Because these screening tools take two 
to five minutes to administer and they have demonstrated a high sensitivity and 
specificity for detecting depression, they are the most commonly used instruments for 
adult depression screening (Maurer, 2012).  Arroll et al. (2010) compared the PHQ-9 and 
another depression screening tool in 2,642 adult patients in primary care.  The results 
exhibited a sensitivity of 86% and specificity of 78% for diagnosing depression of the 
tool when compared with the PHQ-9 (Arroll, et al., 2010).  Thus, the PHQ-9 appeared to 
be a more sensitive and specific tool for diagnosing depression in adult patients (Arroll et 
al., 2010).   
The use of the PHQ screening instrument is effective in identifying women at risk 
for depression during pregnancy and the postpartum period.  Avalos et al., (2016) 
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conducted a retrospective cohort study of approximately 100,000 pregnant females.  In 
their study, the Kaiser Permanente Northern California members screened perinatal 
women with the PHQ-9 during three phases of the Universal Perinatal Depression 
Screening program from 2007-2014 (Avalos et al., 2016).  Patients were screened three 
times during pregnancy and once during the postpartum period.  Avalos et al., (2016) 
found depression screening to be less than 1% for pre-implementation of a developed 
screening program but improved to 98% when a depression screening program was fully 
implemented (p < .001).  In addition, providers began treatment earlier for those 
screening positive and was considered a benefit of the perinatal depression screening 
program (Avalos et al., 2016).  Furthermore, Avalos et. al., (2016) suggested there was an 
improvement for symptom outcomes for perinatal females when identified early from a 
depression screening program.   
A similar outcome was demonstrated by Kroenke et al., (2003).  In their study, the 
PHQ-2 and PHQ-9 questionnaires were completed by 6,000 patients in eight primary care 
clinics and seven OB-GYN clinics (Kroenke et al., 2003).   A self-administered PHQ 
questionnaire found if the scores were greater than three on the PHQ-2, further screening 
using the PHQ-9 was completed (Kroenke et al., 2003).  Results demonstrated a PHQ-2 
score greater than or equal to three had a sensitivity of 83% and a specificity of 92% for 
major depression (Kroenke et al., 2003).  There were comparable results with the PHQ-9 
between the primary care clinics and the OB-GYN clinics (Kroenke et al., 2003).   
Screening for perinatal depression may reduce the symptoms and prevalence of 
depression.  Sit and Wisner (2009) reviewed two cohorts of obstetrical patients who were 
screened for depression using the PHQ-9. For those who screened positive, there was a 
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high overall sensitivity and specificity of 88% for obstetrical patients. (Sit & Wisner, 
2009).  The remission rate for perinatal depression went from 6.2% to 34.6% when 
depression was identified early and treatment was initiated early.  This study 
recommended screening pregnant and postpartum women for depression with the PHQ-2 
or PHQ-9 for early identification and treatment (Sit & Wisner, 2009).    
Similarly, O’Connor, Rossom, Henninger, Groom, and Burda (2016) performed a 
systematic review of pregnant and postpartum females over the age of 18-years who were 
screened for depression.  A total of six trials with two investigators independently 
reviewing the abstracts and full-text articles demonstrated a 2.1% to 9.1% reduction in 
reported depression with programs utilizing a standardized depression screening modality 
(O’Conner et al., 2016).  They found screening pregnant and postpartum women for 
depression may help to reduce depressive symptoms and the prevalence of the disease 
(O’Conner et al., 2016).  Early identification may provide early treatment, thus reducing 
symptoms and preventing the condition from worsening. O’Conner et al., (2016) 
demonstrated pregnant and postpartum women age 18-years or older had an 18% to 59% 
reduction in depressive symptoms when they were screened and treated early for 
depression.   
 Treatment for perinatal or postpartum depression with behavioral therapy and/or 
medication may enhance the care for depression.  Silverman et al., (2017), found 
screening during the perinatal or postpartum period was important, and treatment with 
behavioral therapy and/or medication improved outcomes.  Sit and Wisner (2009) found 
a positive benefit when cognitive behavioral therapy was implemented.   The increase in 
the depression remission rates were 6.2 % to 34% when cognitive behavioral therapy was 
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implemented (Sit & Wisner, 2009).  Furthermore, there is supporting evidence for 
medication therapy such as sertraline, citalopram and escitalopram as being effective and 
safe to use in pregnancy, and they are preferred for medication therapy in pregnancy. 
Grigoriadis et al., (2013) found antidepressant medication during pregnancy was actually 
safer than not treating a female for depression during her pregnancy.  Also, Grigoriadis et 
al., (2013) recommended treatment should start with sertraline if the patient had not used 
an antidepressant previously, but citalopram and escitalopram were reasonable 
alternatives if they had.  Finally, some providers chose to use cognitive behavioral 
therapy in conjunction with medication management (Grigoriadis, et al., 2013).   
For improving the quality of healthcare delivered, the Plan-Do-Study-Act cycle 
(PDSA) is a preferred framework and scientifically valid process for testing change.  The 
PDSA cycle can provide the method for structuring the development of change (Taylor et 
al., 2013).  The PDSA cycle was a result of the work of Deming’s process using the 
structure, process, outcomes method in Japan (Taylor et al., 2013).  The learning and 
improvement in outcomes may be achieved through testing the changes made and 
measuring for improvement using small, incremental changes for each cycle.  In the 
PDSA cycle, measuring outcomes aids in understanding the impact of the intervention 
(Taylor et al., 2013).  Hence, utilizing a PDSA cycle for implementing a standardized, 
valid depression screening tool during the antepartum period may be useful in improving 
outcomes for those affected by perinatal depression.   
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Methods 
Design 
An observational, descriptive, cohort design utilizing a retrospective record 
review was used.  This quality improvement process used a PDSA cycle to implement the 
PHQ-2 and PHQ-9.  This was the first cycle of the quality improvement process.   
Setting 
An organizationally owned, OB-GYN practice in a Midwestern suburb contained 
in a metropolitan area of over three million residents.  The practice employs one nurse 
practitioner, three physicians who are board-certified in OB-GYN, two registered nurses, 
and four medical assistants.  Office hours are Monday through Friday, 0800-1630. 
Pregnant women in the practice deliver at one local hospital in an area with more than ten 
hospitals with obstetrical units.  In the practice there are approximately 40 new pregnant 
patients each month. The total number of patients seen per year is approximately 9,600.   
Sample 
A convenience sample of antepartum patients at/or around 36-weeks gestation 
was studied. Inclusion criteria were pregnant females between the ages of 18-45 years 
who were at or near 36-weeks gestation.  Exclusion criteria were non-pregnant females, 
those below age 18-years and above age 45-years. 
Procedures 
 A team of key stakeholders was formed in September 2018, including the primary 
investigator, practice physicians, nurses, medical assistants and office staff.  There were 
several meetings regarding depression screening, high rates of depression during 
pregnancy, and the PHQ-2 and PHQ-9 as a potential standardized depression screening 
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tool.  A decision was made to utilize and implement the PHQ depression screening tools 
into the practice.  In October 2018, the practice physicians and staff were educated on 
how to access and complete the tool in the electronic health record (EHR).  The process 
agreed upon for utilizing the tool included a physician or nurse completion when a patient 
presented at/or around 36-weeks gestation.  PHQ-2 would be completed initially and if 
positive, the PHQ-9 would appear automatically.  If the PHQ-9 was positive, further 
evaluation would be indicated by the physician or NP provider.  The provider would be 
expected to document medication treatment prescribed or any referral to a mental health 
provider, if either of those treatments would be needed.  The follow-up visit would also 
be documented. 
Data Collection and Analysis 
Data was collected via a retrospective medical record review between January 2nd, 
2019 and March 20th, 2019.  Demographic data included age, race/ethnicity, parity, 
number of live births, and gestational age.  Other data included number of PHQ-2 and 
PHQ-9 screenings completed, depression treatment medications prescribed (if any), and 
referrals for depression as documented in the medical record.  The data was collected and 
stored on a password protected computer and jump drive by the primary investigator.  All 
data was de-identified and coded as 1, 2, 3, 4, etc.  The data was analyzed using 
descriptive statistics and inferential statistics with chi-square.   
Approval Processes 
 Initial approvals were obtained by the doctoral committee and the organizational 
practice where the study was conducted.  In addition, Institutional Review Board (IRB) 
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approval from the University of Missouri-St. Louis (UMSL) was obtained.  Final 
approval from the graduate school at UMSL was also obtained.    
Results 
 The total number of patients who met inclusion criteria between January 2nd and 
March 20th, 2019 was 66; however, the number of patients who were screened for 
depression was 54 (N=54).  Thus, 19% (n=12) of patients meeting the inclusion criteria 
were not screened. The age of the patients ranged from 19-42 years (m=28.6; sd=4.8).  
The number of pregnancies (parity) ranged from one to six (m=1.8; sd=0.9), and the total 
number of live births was zero to two (m=0.63; sd=0.62) for each woman.  Most of the 
women were white (n=40, 74.1%), 20.4% were black (n=11), 3.7% were Asian (n=2) and 
1.9% were another race/ethnicity (n=1). The most frequently observed categories for the 
number of weeks gestation were 35+5 and 36+1 (n=7; 13%) indicating about 26% of 
patients were screened for depression at essentially 36-weeks gestation (appendix A).   
The most frequently observed category of PHQ-2 was negative (n=50, 93%).  Although 
most women tested negative on the prenatal depression screen at 36-weeks gestation, chi 
square test of independence indicated the PHQ-2 identified those at risk and in need of 
further evaluation with the PHQ-9 (χ2=39.19, df=1, p<0.001).  The most frequently 
observed category of PHQ-9 was positive (n=4, 7%). All women who screened positive 
on the PHQ-9 (n=4) for depression were treated (χ2=29.01, df=1, p<0.001); hence, those 
who screened positive for depression were treated with medication, referral, or both 
(appendix B).  There were some patients who were already being treated for depression 
(n=3) prior to screening at 36-weeks gestation; however, there were four patients 
identified to be at risk for moderate to severe depression.  Of those four, all were treated 
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either with medication prescription, referral to a mental health care provider, or both 
(appendix C). 
Discussion 
 There were 66 pregnant patients who met criteria for the depression screening 
during the January 2nd through March 20th, 2019 time frame when the PHQ-2 and PHQ-9 
screening instruments were implemented in a private, organizationally-owned OB-GYN 
practice.  About 80% of the patients meeting the inclusion criteria were screened.  While 
most patients screened negative for being at risk for depression, all of those who screened 
positive on the PHQ-2 had a PHQ-9 administered as recommended. Furthermore, all 
patients who screened positive with the PHQ-9 were prescribed recommended 
medications (i.e., sertraline, citalopram or escitalopram) for treatment along with referral 
to a cognitive behavioral therapist.   
 Implementation of depression screening with a validated instrument found 
approximately one in twenty patients screened positive for depression at/or near 36-
weeks gestation and they received treatment in the antepartum period.  Overall, an 80% 
rate of depression screening using a validated depression screening tool for those at/or 
around 36-weeks gestation when compared to no previous depression screening 
mechanism was a clinically significant success for the practice.  Moreover, the results 
indicated statistically significant results for the PHQ-2 and PHQ-9 (p<0.001) when 
screening for depression in antepartum females at or near 36-weeks gestation.  Screening 
for antepartum depression with the PHQ-2 and PHQ-9 identified patients at risk for 
moderate to severe depression and enabled early treatment.  
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 Use of the PHQ-2 and PHQ-9 were helpful in identifying pregnant females who 
were at risk for depression and enabled medication management and referrals prior to 
delivery. These patients will have several weeks prior to delivery to allow their 
medications to achieve a therapeutic level; however, consideration may be given to 
screening antepartum at or near 34-weeks to improve the therapeutic effects of 
medication prior to the anticipated delivery date.  Furthermore, screening in the 
postpartum period will be important.  The next cycle of the PDSA framework should 
include PHQ screening at or near 6-weeks postpartum to align with the current 
recommendations to screen at least once before and after delivery. Of interest will be the 
comparison of depression screening rates before and after delivery, especially for those 
treated with medications and cognitive behavioral therapy prior to delivery. 
Conclusion 
 This quality improvement initiative found the PHQ depression screening 
instruments to be helpful in identifying one in every 20 pregnant females at risk for 
moderate to severe depression when screened at or near 36-weeks gestation.  Treatment 
with recommended medication and referral to a cognitive behavioral therapist may allow 
for therapeutic effects to occur beyond delivery.  However, these patients were not re-
screened during the postpartum period as the ACOG and USPTF recommended. Early 
screening for depression and early treatment (if needed), may prevent severe postpartum 
depression and subsequent chronic depression beyond the postpartum period, but further 
study is needed to compare antepartum and postpartum depression screening. 
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Appendix A 
Table 1 
Demographics  
Age, Number of Pregnancies, Live Births 
 Minimum Maximum Mean Std. Deviation 
Age 19 42 28.59 4.819 
Pregnancies 1 6 1.80 .898 
Total Live Births 0 2 .63 .623 
 
Race 
            Frequency Percent Valid Percent Cumulative Percent 
 White 40 74.1 74.1 74.1 
Black 11 20.4 20.4 94.4 
Asian 2 3.7 3.7 98.1 
Other 1 1.9 1.9 100.0 
Total 54 100.0 100.0  
 
Weeks Gestation 
 Frequency Percent Valid Percent Cumulative Percent 
Valid 34+6 2 3.7 3.7 3.7 
35+0 3 5.6 5.6 9.3 
35+2 3 5.6 5.6 14.8 
35+3 4 7.4 7.4 22.2 
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35+4 5 9.3 9.3 31.5 
35+5 7 13.0 13.0 44.4 
35+6 4 7.4 7.4 51.9 
36+0 6 11.1 11.1 63.0 
36+1 7 13.0 13.0 75.9 
36+2 3 5.6 5.6 81.5 
36+3 4 7.4 7.4 88.9 
36+4 1 1.9 1.9 90.7 
36+5 1 1.9 1.9 92.6 
36+6 1 1.9 1.9 94.4 
37+0 1 1.9 1.9 96.3 
37+2 1 1.9 1.9 98.1 
37+3 1 1.9 1.9 100.0 
Total 54 100.0 100.0  
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Appendix B 
Table 2 
Depression Screening 
PHQ-2 
 Frequency Percent Valid Percent Cumulative Percent 
Valid Positive 4 7.4 7.4 7.4 
Negative 50 92.6 92.6 100.0 
Total 54 100.0 100.0  
 
PHQ-9 
 Frequency Percent Valid Percent Cumulative Percent 
Valid 
Missing 
4 7.4 100.0 100.0 
50 92.6   
54 100.0   
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Appendix C 
Figure 1.  PHQ 2 and PHQ 9 Screening and Treatment  
 
 
Figure 1.  Some patients were already being treated for depression (n=3) and screened 
negative on the PHQ-2. Those who were not previously treated but tested positive (n=4) 
received treatment either by medication prescription or mental health referral during their 
pregnancy (χ2=29.01, df=1, p < 0.001). 
 
 
 
